Search PubMed⌕ Search

Biomedical subjects

S Pestka

Publications and source records attributed to S Pestka.

At least 109 records · Page 6Linked to original sources
PubMed1989

Modulation of carcinoembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant human gamma-interferon.

Recombinant human interferons have recently been shown to enhance tumor antigen expression, including carcinoembryonic antigen (CEA), on the surface of human carcinoma cells, which results in an increase in the targeting of antitumor monoclonal antibodies (MAb) in vivo. We report here the effect of recombinant human gamma-interferon (HuIFN-gamma) on the expression of human CEA and its related transcripts in several human colon carcinoma and normal human fibroblast cell lines. The colon tumor cell lines HT-29, WiDr, and LS-174T were each shown to express different constitutive levels of CEA glycopeptide, as measured by the binding of the CEA-specific MAb COL-4. Treatment with HuIFN-gamma enhanced the level of binding of COL-4 in total cell extracts of HT-29 and WiDr cells 2.5- and 6.5-fold, respectively. Using a CEA complementary DNA probe, this increase in MAb binding was shown to be accompanied by a 6- to 11-fold increase in the steady state levels of three CEA transcripts with sizes of 4.2, 3.5, and 2.8 kilobases. On the other hand, HuIFN-gamma treatment had no effect on the level of COL-4 binding or expression of CEA transcripts in LS-174T colon carcinoma cells, which are high constitutive expressors of CEA glycoprotein. Normal human fibroblast cell lines MRC-5 and WI38 had no detectable cytoplasmic CEA glycopeptide levels nor did they contain detectable levels of CEA mRNA, either before or after treatment with HuIFN-gamma. In contrast, HuIFN-gamma induced the de novo expression of the normal major histocompatibility complex class II antigen, HLA-DR, on HT-29 and WiDr colon cancer cells as well as the two fibroblast cell lines. Treatment of the LS-174T cell line with HuIFN-gamma did not result in the induction of class II HLA-DR antigen. These observations suggest that some common factors may be involved in the regulation of the CEA and class II histocompatibility genes. In addition, the demonstration that HuIFN-gamma enhances CEA expression in some carcinoma cell lines but fails to induce de novo expression of CEA transcripts in fibroblasts supports the potential application of HuIFN-gamma in enhancement of tumor targeting of antitumor MAbs and adds to our understanding of the mechanism of gamma-interferon-mediated up-regulation of some tumor antigens.

Carcinoembryonic Antigen↗
PubMed1989

Construction and phosphorylation of a fusion protein Hu-IFN-alpha A/gamma.

A protein consisting of human (Hu)-IFN-alpha A to which the COOH-terminal 16 amino acids of Hu-IFN-gamma were fused was prepared by constructing an expression vector by oligonucleotide-directed mutagenesis. The hybrid protein Hu-IFN-alpha A/gamma was expressed under the control of phage lambda PL promoter. The protein was purified with the use of a monoclonal antibody against Hu-IFN-alpha or the COOH-terminal amino acid sequence of Hu-IFN-gamma. The purified protein exhibited a single major band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and has antiviral activity on human and bovine cells. Unlike Hu-IFN-alpha A, but similar to Hu-IFN-gamma, the hybrid Hu-IFN-alpha A/gamma can be phosphorylated by [gamma 32P]ATP and cAMP-dependent protein kinase. The phosphorylated molecule binds to the IFN-alpha/beta receptor. The introduction of a phosphorylation site into Hu-IFN-alpha A by fusion of the region of Hu-IFN-gamma which contains the phosphorylation site provides a new reagent for studies of receptor binding, pharmacokinetics, and other studies where labeled interferons are useful. Furthermore, the introduction of phosphorylation sites into proteins provides a new principle for the preparation of a wide variety of reagents for many purposes.

Amino Acid Sequence↗
PubMed1989

Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells.

Freshly isolated cells from patients with pleural or peritoneal effusions cytologically diagnosed as adenocarcinoma (n = 43), malignant nonepithelial neoplasms (n = 10), and benign (n = 8) were analyzed for expression of constitutive levels of the tumor antigens TAG-72 [recognized by monoclonal antibody (MAb) B72.3] and carcinoembryonic antigen (CEA) (recognized by MAb COL-4) as well as the class I and class II major histocompatibility (MHC) antigens, and the ability of human interferons (Hu-IFNs) to enhance cell surface expression of those antigens as measured by MAb binding. Both type I and type II IFNs enhanced the expression of TAG-72 and CEA and altered the level of expression of the MHC antigens. Comparative studies of three different Hu-IFNs (IFN-alpha A, IFN-beta ser, and IFN-gamma) revealed that IFN-gamma was the most potent in augmenting either B72.3 or COL-4 binding. Unlike the IFN-gamma -mediated induction of the class II human leukocyte antigens, the change in tumor antigen expression consisted of enhanced constitutive antigen expression; de novo induction of either TAG-72 or CEA could not be achieved by either type I or type II IFN. Of 43 effusions isolated from different adenocarcinoma patients, 42 (97.7%) expressed either CEA or TAG-72, and treatment with Hu-IFN increased the level of expression of either antigen in 36 of 42 samples (85.7%). These studies demonstrate the augmentation of tumor-associated antigens on human carcinoma cells isolated from serous effusions by Hu-IFNs which may be used to enhance the targeting of conjugated MAbs to human carcinoma lesions.

Adenocarcinoma↗
PubMed1989

Creation of phosphorylation sites in proteins: construction of a phosphorylatable human interferon alpha.

A phosphorylation site was introduced into human interferon alpha A (IFN-alpha A) by site-specific mutation of the coding sequence. Three slightly different phosphorylation sites were created by using the predicted amino acid consensus sequences for phosphorylation by the cAMP-dependent protein kinase. The resultant modified interferons (IFN-alpha A-P) were expressed in Escherichia coli and purified. The purified proteins exhibit antiviral activity on bovine and human cells similar to that of the unmodified IFN-alpha A. The IFN-alpha A-P proteins can be phosphorylated by the catalytic subunit of cAMP-dependent protein kinase with [gamma-32P]ATP to high specific activity (2000-5000 Ci/mmol; 1 Ci = 37 GBq) with retention of biological activity. The 32P-labeled IFN-alpha A-P proteins bind to cells and can be covalently bound to the IFN-alpha/beta receptor with a bifunctional reagent as can human IFN-alpha A. The introduction of phosphorylation sites into proteins provides a procedure to prepare a large variety of radioactive proteins for research and clinical use.

Amino Acid Sequence↗
PubMed1989

Characterization of human interferon-gamma receptor purified from placenta.

Membranes prepared from human placenta were used for characterization of the receptor for human interferon-gamma (HuIFN-gamma) after large-scale purification. HuIFN-gamma linked covalently to Affigel-10 was used for the purification of the receptor from octylglucoside-solubilized placental membranes. Radiolabeled IFN-gamma [32P]HuIFN-gamma, was used in binding and cross-linking studies to detect the receptor at different stages of the purification. From binding assays it was calculated that an average placenta contained 90-120 micrograms of receptor with a Kd value of 1.3 x 10(-9) M. Thus, human placenta is a rich and convenient source of receptor for IFN- gamma. When purified receptor was cross-linked to [32P]HuIFN-gamma, a variety of cross-linked bands were detected dependent on the preparation conditions. The use of protease inhibitors in the course of processing prevented degradation of the 90-kD intact receptor, showing that the lower-molecular-weight products detected in previous studies are degradation products of the receptor. Furthermore, a 20-kD fragment of the receptor was found to be active in binding HuIFN-gamma.

Cross-Linking Reagents↗
PubMed1988

Correlation of DNA hypomethylation with expression of carcinoembryonic antigen in human colon carcinoma cells.

Using an assay based on the binding of a carcinoembryonic antigen (CEA)-specific monoclonal antibody, we have examined the expression of carcinoembryonic antigen genes in human colon tumor and normal fibroblast cell lines. CEA expression was not detectable in the normal fibroblast cell lines, whereas varying levels of high CEA expression were found in the colon tumor cell lines LS-174T, GEO, and WIDR. We have used a 550-base pair CEA probe derived from cloned complementary DNA to carry out Southern analysis of the DNA isolated from the normal and colon tumor cell lines. At high stringency, the CEA probe detected seven BamHI fragments in all DNAs analyzed. At low stringency, however, 14 BamHI fragments ranging from 1.5 to 23 kilobases were detected. Results of the Southern analysis demonstrate no amplification or rearrangement of the CEA genes in tumor cells. We used methylation-sensitive restriction endonucleases, HpaII and HhaI, to compare the degree of methylation of CEA family of genes in normal and colon tumor cell lines. Our results demonstrate that the CEA family of genes exists in a state of hypermethylation in the normal cell lines. In contrast, the CEA gene(s) are relatively hypomethylated in the tumor cell lines, suggesting a correlation between the state of methylation and degree of expression of the CEA gene(s). A comparison of the state of methylation of the CEA gene(s) in cells before and after treatment with the gamma-interferon (which up-regulates CEA steady-state mRNA levels) showed no detectable difference in the degree of DNA methylation. The segments of CEA genes that are hypermethylated in normal cells, but are hypomethylated in tumor cells, were also identified. Thus, these studies may help identify the sites of methylation that are crucial for the control of CEA gene regulation.

Antibodies, Monoclonal↗
PubMed1988

Expression of the murine interferon gamma receptor in Xenopus laevis oocytes.

This study describes the isolation of mRNA for the murine interferon gamma receptor and its expression in frog oocytes. The binding properties and apparent molecular weight of the murine interferon gamma receptor protein synthesized in frog oocytes is similar to that found on mouse cells. This is the first report of a functional receptor for a polypeptide ligand (interferon gamma) expressed in and directly assayed on frog oocytes.

Animals↗
PubMed1988

Direct nanogram quantitation of nucleic acid and protein with a continuous-flow microcell.

A simple method for rapid nanogram measurement of nucleic acids and proteins is described. It requires only 5 to 10 microliter of sample solution which is injected into the postcolumn flow stream of a high-performance liquid chromatograph. Samples are analyzed by uv detection at 260 nm for nucleic acids and 280 nm for proteins with a diode array detector. Analyzing speed is two samples per minute and the amount to be analyzed ranges from 3 ng to 80 micrograms for nucleic acids and 10 ng to 80 micrograms for bovine serum albumin, irrespective of the sample volume. The method is particularly useful for fast, accurate, and trace amount measurement of purified DNA, RNA, and protein samples in small volumes.

Chromatography, High Pressure Liquid↗
PubMed1988

Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon.

The effects of recombinant human leukocyte (clone A) interferon (rHu-IFN-alpha A) were investigated on the expression of monoclonal antibody (MAb)-defined tumor antigens expressed on human mammary and colon carcinomas. The rHu-IFN-alpha A treatment substantially increased the localization of radiolabeled MAb B6.2-F(ab')2 to the transplantable Clouser human mammary carcinoma, as well as to the moderately differentiated human colon xenograft WiDr, when grown as s.c. tumors in athymic mice. In contrast, human tumor cell lines (i.e., LS174T, A375, etc.) that were unresponsive to the antigen-augmenting ability of rHu-IFN-alpha A in vitro were also unresponsive in vivo, indicating a possible method of screening carcinoma cell populations for subsequent rHu-IFN-alpha A adjuvant therapy prior to MAb administration. The method of delivery of rHu-IFN-alpha A was also studied. The i.m. route resulted in a 3-4 h plasma half-life for rHu-IFN-alpha A. The administration of rHu-IFN-alpha A via an osmotic pump resulted in a stable circulating plasma titer of 400-800 antiviral units/ml for 7 days. Utilizing delivery of rHu-IFN-alpha A by the constant infusion route, it was found that the increase in localization of 125I-B6.2-F(ab')2 was dependent on (1) the length of time of treatment and (2) the circulating plasma rHu-IFN-alpha A levels. These results thus provide information useful for subsequent studies to determine the potential efficacy of adjuvant rHu-IFN-alpha A treatment for MAb-targeted tumor diagnosis and treatment.

Adjuvants, Immunologic↗
PubMed1988

Chromosome mapping of biological pathways by fluorescence-activated cell sorting and cell fusion: human interferon gamma receptor as a model system.

Human chromosome 6 encodes both the interferon gamma receptor as well as the class I major histocompatibility complex antigens, HLA-A, -B, and -C. However, the presence of chromosome 6 in somatic cell hybrids is insufficient to confer sensitivity to human interferon gamma (Hu-IFN-gamma) as assayed by class I HLA induction; it is necessary for both human chromosomes 6 and 21 to reside in the hybrid to generate a response to Hu-IFN-gamma. Treatment of such a hamster-human hybrid, Q72-18, with Hu-IFN-gamma induces the class I HLA antigens. Q72-18 cells selected by fluorescence-activated cell sorting for the loss of class I HLA induction also lost human chromosome 21. Fusions of such cells to a hybrid that contains only human chromosome 21 reconstitutes HLA antigen induction by Hu-IFN-gamma. Furthermore, fusions of hybrids containing a translocated human chromosome 6q and the HLA-B7 gene to a line containing only human chromosome 21 or a translocated 21q also reconstitutes HLA-B7 mRNA and antigen induction by Hu-IFN-gamma. Thus the segregation of cells on the basis of a biological effect by fluorescence-activated cell sorting and reconstitution by hybrid fusion provides a strategy by which some biological pathways can be mapped at a chromosomal level.

Blotting, Northern↗
PubMed1988

Detection of human leukocyte interferon-alpha A and -alpha 2 genes in genomic DNAs by the use of deoxyoctadecyloligonucleotide probes.

Two deoxyoctadecyloligonucleotides complementary to the sequence spanning a single base substitution between human leukocyte interferon (HuIFN) alpha A and alpha 2 genes were efficiently used as probes to distinguish between HuIFN-alpha A and -alpha 2 genes. At 37 degrees C or 42 degrees C under aqueous conditions (0.9 M NaCl), hybridization between both probes and the alpha A and alpha 2 genes without any mismatch was strong, whereas the hybridization with one base mismatch (alpha A probe-alpha 2 gene and alpha 2 probe-alpha A gene) was very weak or negligible. Because the single base substitution of G in the alpha 2 gene for A in the alpha A gene provides an extra HinfI site in the alpha 2 gene at the center of the sequence hybridizing to the alpha 2 probe, digestion with HinfI restriction endonuclease caused complete loss of the hybridization between the alpha 2 probe and the alpha 2 gene. PvuII digestion provides 298-bp fragments hybridizing to the probes only from the alpha A and alpha 2 genes among the known HuIFN-alpha genes. Thus, with the use of these oligonucleotide probes in combination with PvuII and PvuII-HinfI restriction endonuclease digestion, the existence of the sequences corresponding to both IFN-alpha A and IFN-alpha 2 genes in human genomic DNAs was demonstrated. The results also surprisingly indicate that these genes, formerly considered alleles because of their essential identity (1 base pair difference in the coding sequence), are not likely to be alleles, but represent closely related distinct genes.

DNA Restriction Enzymes↗
PubMed1988

Recombinant rat and murine immune interferons are phosphorylated at a single site, Ser132.

Recombinant rat (Ra) and murine (Mu) immune interferons (IFN-gamma) were found to be phosphorylated by bovine heart muscle cAMP-dependent protein kinase at a single site, in contrast to human (Hu) IFN-gamma, which was reported to be phosphorylated at two different serine residues. Chromatography of a Staphylococcal aureus V8 protease digest of Ra or MuIFN-gamma indicated that the site of phosphorylation was in the carboxy-terminal undecamer fragment of the protein. Due to inherent problems in measuring both phenylthiohydantoin-serine (PTH-serine) and PTH-phosphoserine with an automated sequenator, a novel approach, involving partial Edman degradation of aliquots of the peptide followed by high performance liquid chromatography (HPLC) analysis, was developed. It was determined that Ser132 is the exclusive site of phosphorylation for both IFNs.

Amino Acid Sequence↗
PubMed1988

Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons.

Eight different human breast carcinoma cell lines, as well as clonally derived cell lines, were used to study the expression of four different monoclonal antibody (MAb)-defined tumor-associated antigens (TAAs) and the ability of recombinant human (rHu)-interferon (IFN)-alpha A and rHu-IFN-gamma to increase tumor-associated and/or normal cell-surface antigen expression. The different breast tumor cell lines expressed a wide range of antigenic phenotypes with respect to four different cell-surface TAAs. The cell lines could be divided into high and low antigen-expressing groups based on their constitutive levels of the four TAAs. In general, those breast tumor cell lines that expressed high levels of carcinoembryonic antigen, the MAb DF-3-defined 290-kD antigen, and the 90-kD antigen reactive with MAb B6.2 were poor candidates for antigen augmentation by rHu-IFN-alpha A or rHu-IFN-gamma. In contrast, breast cell lines that constitutively express low levels of these TAAs were found to be highly responsive to the ability of either of the rHu-IFNs to enhance MAb binding to the cell surface. Treatment with either of the rHu-IFNs increased the level of surface binding of MAbs as much as fourfold. The relative abilities of the IFNs to increase MAb binding to the surface of human breast tumor cells thus appeared to depend on the degree of constitutive surface antigen expression of the breast tumor cells. The high-molecular-weight TAA, TAG-72, is known not to be expressed on most cell lines but is expressed on the majority of human carcinoma biopsies. Most breast tumor cell lines employed in this study did not express the TAG-72 high-molecular-weight TAA. However, rHu-IFN-alpha A did substantially increase the level of expression of TAG-72 on the surface of breast tumor cells that were isolated from a pleural effusion. These studies may thus provide an important insight into the criteria used in the selection of carcinoma patients for IFN-mediated antigen augmentation when employing MAb-guided radioimmunolocalization or MAb-guided therapy.

Antibodies, Monoclonal↗
PubMed1987

The mouse immune interferon receptor gene is located on chromosome 10.

When mouse L cells are incubated with 32P-labeled recombinant murine immune interferon ( [32P]Mu-IFN-gamma) and subsequently cross-linked with disuccinimidyl suberate, a major complex with an apparent molecular mass of 95,000-125,000 daltons can be visualized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The complex was not formed when the binding was performed in the presence of excess unlabeled Mu-IFN-gamma or when Chinese hamster ovary cells were used. This complex therefore represents the Mu-IFN-gamma receptor (or its interferon-binding subunit). The chromosomal location of the Mu-IFN-gamma receptor (or the binding subunit of the receptor) gene, termed Ifgr, was identified by performing the binding and cross-linking reactions on a series of mouse-hamster somatic cell hybrids with different subsets of mouse chromosomes. The presence of mouse chromosome 10 was shown to be necessary and sufficient for the formation of the cross-linked complex. Thus, the gene coding for the binding subunit of the Mu-IFN-gamma receptor was localized to mouse chromosome 10. The presence of this chromosome in the hybrid cells was not sufficient, however, to confer antiviral resistance to the hybrids when they were treated with Mu-IFN-gamma and challenged with encephalomyocarditis virus.

Animals↗
PubMed1987

Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo.

Heterogeneity in the expression of tumor-associated antigens, as defined by the binding of monoclonal antibodies, is a characteristic common to most, if not all, human carcinoma cell populations. Antigen-negative cells within the population can escape detection and therapy by their failure to bind the appropriate antibody. Therefore, the extent of antigenic heterogeneity is an important consideration when designing protocols for the management of cancer by administration of monoclonal antibodies. One approach to counteracting the effect of antigenic heterogeneity is the use of clone A of recombinant human leukocyte interferon (Hu-IFN-alpha A). Administration of Hu-IFN-alpha A in vivo effectively increased the amount of tumor antigen expressed by a human colon xenograft in situ and augmented the localization of a radiolabeled monoclonal antibody to the tumor site. Concomitant administration of Hu-IFN-alpha A and monoclonal antibody may thus be effective in overcoming the antigenic heterogeneity of carcinoma cell populations and in enhancing the efficacy of monoclonal antibodies in the detection and treatment of carcinoma lesions.

Animals↗
PubMed1987

Human chromosomes 6 and 21 are required for sensitivity to human interferon gamma.

The human interferon gamma receptor has previously been assigned to chromosome 6. Chromosome 6 also encodes HLA, the human class I major histocompatibility antigens. However, the presence of chromosome 6 in hamster-human hybrids is by itself insufficient to confer sensitivity to human immune interferon as measured by the induction of human HLA. Human chromosome 21 was found to be the second chromosome essential for HLA inducibility. Similar results were found with mouse-human somatic cell hybrids. Thus, at least two steps are involved in the action of human interferon gamma: the binding of interferon gamma to its receptor coded by chromosome 6 and the linkage of this binding event through a factor coded by chromosome 21 to trigger biological action. Both of these steps are species-specific.

Animals↗
PubMed1987

Expression of a pseudogene for interferon-alpha L.

The human leukocyte interferon-alpha L (IFN-alpha L) appears to be a pseudogene because it contains a termination codon in the DNA coding for the precursor peptide (signal peptide), but the remainder of the gene codes for an interferon protein of normal length. To determine if this gene codes for an active interferon molecule, an expression plasmid was constructed for IFN-alpha L that was produced in Escherichia coli. The IFN-alpha L is active on human and bovine cells, and exhibits a trace of activity on mouse cells.

Cloning, Molecular↗